Richard Lerner, antibody pioneer and longtime president of Scripps Research, dies at 83

Josh Sullivan

Richard Lerner, the esteemed biochemist who pioneered a new way to develop monoclonal antibodies and led Scripps Research Institute to prominence, has passed away. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Richard Lerner, antibody pioneer and longtime president of Scripps Research, dies at 83

Josh Sullivan

Sign up to read this article for free.

Pfizer to invest $1B in China over next five years — reports

Senior AstraZeneca exec detained in China amid wider investigation

Avid Bioservices to be sold to private equity firms for $1.1B

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Richard Lern­er, an­ti­body pi­o­neer and long­time pres­i­dent of Scripps Re­search, dies at 83

Josh Sullivan

Sign up to read this article for free.

Pfiz­er to in­vest $1B in Chi­na over next five years — re­ports

Se­nior As­traZeneca ex­ec de­tained in Chi­na amid wider in­ves­ti­ga­tion

Avid Bioser­vices to be sold to pri­vate eq­ui­ty firms for $1.1B

Soft RSV sales re­veal a vac­cine mar­ket fail­ing to catch post-Covid mo­men­tum

Q&A: Demis Has­s­abis talks win­ning the No­bel Prize, build­ing an AI biotech sans lab, and Trump’s po­ten­tial im­pact

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Richard Lerner, antibody pioneer and longtime president of Scripps Research, dies at 83

Pfizer to invest $1B in China over next five years — reports

Senior AstraZeneca exec detained in China amid wider investigation

Avid Bioservices to be sold to private equity firms for $1.1B

Soft RSV sales reveal a vaccine market failing to catch post-Covid momentum

Q&A: Demis Hassabis talks winning the Nobel Prize, building an AI biotech sans lab, and Trump’s potential impact

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks